These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 31044094)

  • 21. [Osteocyte and DMP1].
    Toyosawa S; Oya K; Sato S; Ishida K
    Clin Calcium; 2012 May; 22(5):713-20. PubMed ID: 22549196
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased Circulating FGF23 Does Not Lead to Cardiac Hypertrophy in the Male Hyp Mouse Model of XLH.
    Liu ES; Thoonen R; Petit E; Yu B; Buys ES; Scherrer-Crosbie M; Demay MB
    Endocrinology; 2018 May; 159(5):2165-2172. PubMed ID: 29635291
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lipocalin-2: a novel link between the injured kidney and the bone.
    Courbon G; David V
    Curr Opin Nephrol Hypertens; 2022 Jul; 31(4):312-319. PubMed ID: 35727169
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How FGF23 shapes multiple organs in chronic kidney disease.
    Leifheit-Nestler M; Haffner D
    Mol Cell Pediatr; 2021 Sep; 8(1):12. PubMed ID: 34536161
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism.
    Feng JQ; Ward LM; Liu S; Lu Y; Xie Y; Yuan B; Yu X; Rauch F; Davis SI; Zhang S; Rios H; Drezner MK; Quarles LD; Bonewald LF; White KE
    Nat Genet; 2006 Nov; 38(11):1310-5. PubMed ID: 17033621
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Functional heterogeneity of osteocytes in FGF23 production: the possible involvement of DMP1 as a direct negative regulator.
    Lee JW; Yamaguchi A; Iimura T
    Bonekey Rep; 2014; 3():543. PubMed ID: 24991406
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Osteocytic protein expression response to doxercalciferol therapy in pediatric dialysis patients.
    Pereira RC; Jüppner H; Gales B; Salusky IB; Wesseling-Perry K
    PLoS One; 2015; 10(3):e0120856. PubMed ID: 25774916
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney Disease-A Pediatric Perspective.
    Grund A; Sinha MD; Haffner D; Leifheit-Nestler M
    Front Pediatr; 2021; 9():702719. PubMed ID: 34422725
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of Altered Mineral Metabolism on Pathological Cardiac Remodeling in Elevated Fibroblast Growth Factor 23.
    Leifheit-Nestler M; Richter B; Basaran M; Nespor J; Vogt I; Alesutan I; Voelkl J; Lang F; Heineke J; Krick S; Haffner D
    Front Endocrinol (Lausanne); 2018; 9():333. PubMed ID: 29977226
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes of FGF23 and the Renin-Angiotensin-System in Male Mouse Models of Chronic Kidney Disease and Cardiac Hypertrophy.
    Okamoto K; Fujii H; Watanabe K; Goto S; Kono K; Nishi S
    J Endocr Soc; 2022 Feb; 6(2):bvab187. PubMed ID: 35047715
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Osteocyte Protein Expression Is Altered in Low-Turnover Osteoporosis Caused by Mutations in WNT1 and PLS3.
    Wesseling-Perry K; Mäkitie RE; Välimäki VV; Laine T; Laine CM; Välimäki MJ; Pereira RC; Mäkitie O
    J Clin Endocrinol Metab; 2017 Jul; 102(7):2340-2348. PubMed ID: 28379384
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted Disruption of NF1 in Osteocytes Increases FGF23 and Osteoid With Osteomalacia-like Bone Phenotype.
    Kamiya N; Yamaguchi R; Aruwajoye O; Kim AJ; Kuroyanagi G; Phipps M; Adapala NS; Feng JQ; Kim HK
    J Bone Miner Res; 2017 Aug; 32(8):1716-1726. PubMed ID: 28425622
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice.
    Liu S; Tang W; Zhou J; Vierthaler L; Quarles LD
    Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1636-44. PubMed ID: 17848631
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease.
    Stubbs J; Liu S; Quarles LD
    Semin Dial; 2007; 20(4):302-8. PubMed ID: 17635819
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Elevated Fibroblast Growth Factor 23 Concentration: Prediction of Mortality among Chronic Kidney Disease Patients.
    Chathoth S; Al-Mueilo S; Cyrus C; Vatte C; Al-Nafaie A; Al-Ali R; Keating BJ; Al-Muhanna F; Al Ali A
    Cardiorenal Med; 2015 Dec; 6(1):73-82. PubMed ID: 27194998
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Altered Osteocyte-Specific Protein Expression in Bone after Childhood Solid Organ Transplantation.
    Pereira RC; Valta H; Tumber N; Salusky IB; Jalanko H; Mäkitie O; Wesseling Perry K
    PLoS One; 2015; 10(9):e0138156. PubMed ID: 26390291
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FGF23 and Klotho in chronic kidney disease.
    Olauson H; Larsson TE
    Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):397-404. PubMed ID: 23666415
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association between FGF23, α-Klotho, and Cardiac Abnormalities among Patients with Various Chronic Kidney Disease Stages.
    Tanaka S; Fujita S; Kizawa S; Morita H; Ishizaka N
    PLoS One; 2016; 11(7):e0156860. PubMed ID: 27400031
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interleukin-6 contributes to the increase in fibroblast growth factor 23 expression in acute and chronic kidney disease.
    Durlacher-Betzer K; Hassan A; Levi R; Axelrod J; Silver J; Naveh-Many T
    Kidney Int; 2018 Aug; 94(2):315-325. PubMed ID: 29861060
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The FGF23-Klotho axis and cardiac tissue Doppler imaging in pediatric chronic kidney disease-a prospective cohort study.
    Tranæus Lindblad Y; Olauson H; Vavilis G; Hammar U; Herthelius M; Axelsson J; Bárány P
    Pediatr Nephrol; 2018 Jan; 33(1):147-157. PubMed ID: 28795324
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.